Drug Trial Radar · NCT07328581
A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- iCell Gene TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase IIa, open-label, single-arm study includes an initial Safety Run-In followed by dose expansion to evaluate the safety, tolerability, cellular kinetics, pharmacodynamics, and preliminary clinical activity of a single infusion of ICG318 in participants with refractory SLE, with or without LN. Participants will receive protocol-specified lymphodepletion followed by ICG318 at the recommended Phase 2 dose.
Conditions
- Systemic Lupus Erythematosus (SLE)
- Lupus Nephritis (LN)
Interventions
ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletionBiological
Anti-BCMA, Anti-CD19 Compound CAR-T Cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse Events after ICG318 infusionTime frame: Starting day 0 and up to 1 year after ICG318 infusion.
- DORIS remission rateTime frame: Starting day 0 and assessed at 6 months, and 1 year after ICG318 infusion.
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of Chicago
Chicago, Illinois · Not yet recruiting
New York Medical College
Hawthorne, New York · Not yet recruiting
NorthWell
New Hyde Park, New York · Recruiting
Fox Chase Cancer Center- Temple BMT
Philadelphia, Pennsylvania · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.